NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 178)
Posted On: 08/14/2019 4:06:35 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Consumer Packaged Goods Veteran to Board of Directors
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing Lexaria and Altria business relationship was negotiated. Quigley is a 20-year Consumer Packaged Goods veteran with a background of managing complex regulatory environments including for novel and innovative nicotine products, and holds additional deep experience with operations and marketing. “Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” Lexaria Chairman of the Board Chris Bunka said in the news release. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing Lexaria and Altria business relationship was negotiated. Quigley is a 20-year Consumer Packaged Goods veteran with a background of managing complex regulatory environments including for novel and innovative nicotine products, and holds additional deep experience with operations and marketing. “Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” Lexaria Chairman of the Board Chris Bunka said in the news release. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼